Interleukin-13 inhibits cytokines synthesis by blocking nuclear factor-κB and c-Jun N-terminal kinase in human mesangial cells

Journal of Biomedical Research

Volumn 24, Issue 4, 2010, Pages 308-316

  Zhu, Chunhua ^a,b   Zhang, Aihua ^a,b   Huang, Songming ^a,b   Ding, Guixia ^a,b   Pan, Xiaoqin ^b   Chen, Ronghua ^b  

^a CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Interleukin 13; Mesangial cells

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P50; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA BINDING; ELECTROPHORETIC MOBILITY; ENZYME ACTIVATION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RIBONUCLEASE PROTECTION ASSAY;

EID: 78549241980     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1674-8301(10)60043-7     Document Type: Article

References (35)

1. Karkar A Modulation of renal inflammation: therapeutic strategies. Saudi J Kidney Dis Transpl 2008, 19:1-19.
2. Lan HY Role of macrophage migration inhibition factor in kidney disease. Nephron Exp Nephrol 2008, 109:e79-e83.
3. Ernandez T, Mayadas TN Immunoregulatory role of TNFalpha in inflammatory kidney diseases. Kidney Int 2009, 76:262-276.
4. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993, 362:248-250.
5. Sikora JP, Kuzanski W, Andrzejewska E Soluble cytokine receptors sTNFR I and sTNFR II, receptor antagonist IL-1ra, and anti-inflammatory cytokines IL-10 and IL-13 in the pathogenesis of systemic inflammatory response syndrome in the course of burns in children. Med Sci Monit 2009, 15:CR26-CR31.
6. Saura M, Martinez-Dalmau R, Minty A, Perez-Sala D, Lamas S Interleukin-13 inhibits inducible nitric oxide synthase expression in human mesangial cells. Biochem J 1996, 313(Pt 2):641-646.
7. Lentsch AB, Shanley TP, Sarma V, Ward PA In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 1997, 100:2443-2448.
8. Herbein G, Varin A, Fulop T NF-kappaB, AP-1, Zinc-deficiency and aging. Biogerontology 2006, 7:409-419.
9. Maziere C, Maziere JC Activation of transcription factors and gene expression by oxidized low-density lipo-protein. Free Radic Biol Med 2009, 46:127-137.
10. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999, 10:529-537.
11. Di Marco GS, Naffah-Mazzacoratti Md Mda G, Vio CP, Dos Santos OF, Schor N, Casarini DE Mesangial cells are able to produce catecholamines in vitro. J Cell Biochem 2003, 89:144-151.
12. Manna SK, Aggarwal BB IL-13 suppresses TNF-induced activation of nuclear factor-kappa B, activation protein-1, and apoptosis. J Immunol 1998, 161:2863-2872.
13. Lin WN, Luo SF, Lin CC, Hsiao LD, Yang CM Differential involvement of PKC-dependent MAPKs activation in lipopolysaccharide-induced AP-1 expression in human tracheal smooth muscle cells. Cell Signal 2009, 21:1385-1395.
14. Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D, et al. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem 2010, 285:10273-10280.
15. Elnaggar R, Hanawa H, Liu H, Yoshida T, Hayashi M, Watanabe R, et al. The effect of hydrodynamics-based delivery of an IL-13-Ig fusion gene for experimental autoimmune myocarditis in rats and its possible mechanism. Eur J Immunol 2005, 35:1995-2005.
16. Matsumoto K, Ohi H, Kanmatsuse K Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 1997, 77:212-218.
17. Kato A, Okaya T, Lentsch AB Endogenous IL-13 protects hepatocytes and vascular endothelial cells during ischemia/reperfusion injury. Hepatology 2003, 37:304-312.
18. de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993, 151:6370-6381.
19. Striz I, Mio T, Adachi Y, Robbins RA, Romberger DJ, Rennard SI IL-4 and IL-13 stimulate human bronchial epithelial cells to release IL-8. Inflammation 1999, 23:545-555.
20. Gu N, Kang G, Jin C, Xu Y, Zhang Z, Erle DJ, et al. Intelectin is required for IL-13-induced monocyte chemotactic protein-1 and - 3 expression in lung epithelial cells and promotes allergic airway inflammation. Am J Physiol Lung Cell Mol Physiol 1999, 298:L290-L296.
21. Steube KG, Meyer C, Drexler HG Constitutive protein expression of monocyte chemotactic protein-1 (MCP-1) by myelomonocytic cell lines and regulation of the secretion by anti-and proinflammatory stimuli. Leuk Res 1999, 23:843-849.
22. Sandovici M, Henning RH, van Goor H, Helfrich W, de Zeeuw D, Deelman LE Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. Kidney Int 2008, 73:1364-1373.
23. Tipping PG, Kitching AR Glomerulonephritis, Th1 and Th2: what's new?. Clin Exp Immunol 2005, 142:207-215.
24. Karkar AM, Tam FW, Steinkasserer A, Kurrle R, Langner K, Scallon BJ, et al. Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Kidney Int 1995, 48:1738-1746.
25. Rusai K, Huang H, Sayed N, Strobl M, Roos M, Schmaderer C, et al. Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Transpl Int 2008, 21:572-580.
26. Fujinaka H, Yamamoto T, Takeya M, Feng L, Kawasaki K, Yaoita E, et al. Suppression of anti-glomerular basement membrane nephritis by administration of antimonocyte chemoattractant protein-1 antibody in WKY rats. J Am Soc Nephrol 1997, 8:1174-1178.
27. Rawlins JT, Opperman LA Tgf-beta regulation of suture morphogenesis and growth. Front Oral Biol 2008, 12:178-196.
28. Omwandho CO, Konrad L, Halis G, Oehmke F, Tinneberg HR. Role of TGF-betas in normal human endometrium and endometriosis. Hum Reprod 25:101-9.
29. Schnaper HW, Jandeska S, Runyan CE, Hubchak SC, Basu RK, Curley JF, et al. TGF-beta signal transduction in chronic kidney disease. Front Biosci 2009, 14:2448-2465.
30. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA Anti-inflammatory and proinflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 2009, 9:447-453.
31. Andrews AL, Nordgren IK, Kirby I, Holloway JW, Holgate ST, Davies DE, et al. Cytoplasmic tail of IL-13Ralpha2 regulates IL-4 signal transduction. Biochem Soc Trans 2009, 37:873-876.
32. Shinozaki S, Mashima H, Ohnishi H, Sugano K IL-13 promotes the proliferation of rat pancreatic stellate cells through the suppression of NF-kappaB/TGF-beta1 pathway. Biochem Biophys Res Commun 2010, 393:61-65.
33. Lan Y, Zhou Q, Wu ZL NF-kappa B involved in transcription enhancement of TGF-beta 1 induced by Ox-LDL in rat mesangial cells. Chin Med J (Engl) 2004, 117:225-230.
34. Deepak P, Kumar S, Acharya A Interleukin-13-induced type II polarization of inflammatory macrophages is mediated through suppression of nuclear factor-kappaB and preservation of IkappaBalpha in a T cell lymphoma. Clin Exp Immunol 2007, 149:378-386.
35. Li X, Stark GR NFkappaB-dependent signaling pathways. Exp Hematol 2002, 30:285-296.